Dr. Marwa Tantawy has a position as a research assistant professor and is currently working at the Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida (UF). She received her master’s degree in immunology in 2010 from the College of Science, Cairo University, Egypt, and her Ph.D. in molecular biology in 2016 from the College of Science, Ain Shams University, Egypt. Before Joining the UF Faculty in 2023, she completed a three-year post-doctoral fellowship in cardiovascular pharmacogenomics at the UF Pharmacotherapy and Translational Research Department. She has expertise in molecular oncology and laboratory experiments, particularly genetic association studies, including genome-wide association analyses (GWAS), genotyping, miRNA sequencing, Next Generation Sequencing, methylation, and cell culture. Her current research focuses on adverse drug events such as cardiotoxicity related to cancer treatment, with a particular emphasis on multi-omics (genomics, epigenomics, metabolomics, and proteomics) to identify early detection markers that help in treatment management and reveal the underlying mechanisms.
Dr. Danxin Wang has a position as an associate professor and is currently working at the Department of Pharmacotherapy and Translational Research, University of Florida. She received her MD degree from Fudan University Medical School and her Ph.D. from the Academy of Military Medical Science in Beijing. She conducted postdoctoral training at the University of California San Francisco. She was a Research Assistant Professor at Ohio State University, Department of Cancer Biology and Genetics, and Associate Director of the Center for Pharmacogenomics prior to joining the University of Florida. Her research interests are the discovery of genetic biomarkers for personalized drug therapy. She has discovered many functional regulatory variants in genes related to drug therapy in the areas of cardiovascular diseases, mental diseases, and drug dependence. Some of these functional variants are currently included in biomarker testing panels to predict drug response. Funded by NIH R01 and R35 awards, her current research is focused on understanding factors controlling the expression of cytochrome P450 drug metabolizing enzymes (CYPs) in the liver. She has served as an Associate Editor of the “European Journal of Pharmaceutical Sciences” and was on the Editorial Board of the “Journal of Pharmacogenomics and Pharmacoproteomics”. She has also served as a grant reviewer for NIH.
Dr. Yan Gong has a position as an Associate Professor and is currently working at the Department of Pharmacotherapy and Translational Research at the University of Florida (UF) College of Pharmacy and the UF Center for Pharmacogenomics and Precision Medicine. She obtained a master’s degree in Statistics and a Ph.D. in Pharmaceutics from UF. She then completed one year of post-doctoral Fellowship in Cardiovascular Pharmacogenomics at the UF Center for Pharmacogenomics. Her research focuses on pharmacogenomics of efficacy and adverse response of antihypertensives medications and pharmacogenomics of serious adverse drug events such as medication-related osteonecrosis of the jaw (MRONJ) and cardiotoxicities related to cancer therapies (Cardio-Oncology). She has authored over 190 peer-reviewed publications. In addition to research, she has been involved in teaching multiple graduate-level courses at the UF College of Pharmacy and College of Medicine.
